Tsubota Laboratory to Recognize Revenue From Final Milestone Achievement With Overseas Pharma Firm

TOKYO, Jul 02 (Pulse News Wire) – Tsubota Laboratory Incorporated (4890.T) announced that it has achieved the final milestone under a licensing agreement with an overseas pharmaceutical firm based on the completion of data delivery and acceptance. As a result, the company plans to recognize revenue related to this milestone in the first quarter of the fiscal year ending March 2027.

This achievement marks a significant step in leveraging research and development data as a valuable asset through collaboration with external companies. It also underscores the progress of internally developed projects and strengthens the company's position in the industry. Moving forward, Tsubota Laboratory will continue to maximize pipeline value by fostering partnerships and licensing activities both domestically and internationally.

Regarding the licensed entity and contract conditions, detailed information such as the nature of the data involved, contractual terms, and payment amounts remains confidential due to non-disclosure agreements. While the expected sales from this transaction are already reflected in the company’s forecast for the fiscal year ending March 2027, Tsubota Laboratory views this as a crucial demonstration of the utility and commercial potential of its proprietary data. The company intends to further capitalize on these assets going forward.

Any additional relevant information will be disclosed promptly.